The Female Health Company To Report First Quarter Operating Results on Wednesday, January 30, 2013
Investor Conference Call Scheduled for 11:00 a.m. EST
Jan 23, 2013
CHICAGO, Jan. 23, 2013 /PRNewswire/ -- The Female Health Company (NASDAQ-CM: FHCO) today announced that it will host an investor conference call to discuss its operating results for the first quarter of FY2013 on Wednesday, January 30, 2013 at 11:00 a.m. Eastern Time (EST). The Company expects to report its operating results earlier the same day.
Shareholders and other interested parties may participate in the conference call by dialing 1-877-374-8416 (international participants dial 1-412-317-6716) and asking to be connected to "The Female Health Company Conference Call" a few minutes before 11:00 a.m. EST on January 30, 2013.
A replay of the call will be available one hour after the call through 9:00 a.m. EST on Wednesday, February 6, 2013 by dialing 877-344-7529 (international callers dial 412-317-0088) and entering the conference ID # 10023963. After February 6, 2013, the replay of the call will be available on the Company's website at www.femalehealth.com.
About The Female Health Company
The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2), which is available in the U.S. and approximately 138 other countries globally. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued by the U.S., the European Union, Canada, Australia, South Africa, Japan, The People's Republic of China, Spain, Mexico, Greece, Turkey and the African Regional Intellectual Property Organization (ARIPO), which includes Botswana, The Gambia, Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Sierra Leona, Sudan, Swaziland, Uganda, Tanzania, Zambia and Zimbabwe. FC2 patent applications are pending in various countries. The FC2 Female Condom® is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:
The statements in this release which are not historical facts are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.
For more information about The Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com.
SOURCE The Female Health Company
For further information: William R. Gargiulo, Jr., +1-231-526-1244, or Michele Greco, CFO, +1-312-595-9123